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Abstract
Background: The HIV-1 accessory protein Nef is an important determinant of lentiviral pathogenicity that
contributes to disease progression by enhancing viral replication and other poorly understood mechanisms. Nef
mediates diverse functions including downmodulation of cell surface CD4 and MHC Class I, enhancement of viral
infectivity, and enhancement of T cell activation. Nef interacts with a multiprotein signaling complex that includes
Src family kinases, Vav1, CDC42, and activated PAK2 (p21-activated kinase 2). Although previous studies have
attempted to identify a biological role for the Nef-PAK2 signaling complex, the importance of this complex and its
constituent proteins in Nef function remains unclear.
Results: Here, we show that Nef mutants defective for PAK2-association, but functional for CD4 and MHC Class I
downmodulation and infectivity enhancement, are also defective for the ability to enhance viral replication in
primary T cells that are infected and subsequently activated by sub-maximal stimuli (1 μg/ml PHA-P). In contrast,
these Nef mutants had little or no effect on HIV-1 replication in T cells activated by stronger stimuli (2 μg/ml PHA-
P or anti-CD3/CD28-coated beads). Viruses bearing wild-type Nefs, but not Nef mutants defective for PAK2
association, enhanced NFAT and IL2 receptor promoter activity in Jurkat cells. Moreover, expression of wild-type
Nefs, but not mutant Nefs defective for PAK2 association, was sufficient to enhance responsiveness of primary CD4
and CD8 T cells to activating stimuli in Nef-expressing and bystander cells. siRNA knockdown of PAK2 in Jurkat
cells reduced NFAT activation induced by anti-CD3/CD28 stimulation both in the presence and absence of Nef,
and expression of a PAK2 dominant mutant inhibited Nef-mediated enhancement of CD25 expression.
Conclusion: Nef-mediated enhancement of cellular activation and viral replication in primary T cells is dependent
on PAK2 and on the strength of the activating stimuli, and correlates with the ability of Nef to associate with PAK2.
PAK2 is likely to play a role in Nef-mediated enhancement of viral replication and immune activation in vivo.
Introduction
The HIV-1 accessory protein Nef is an important deter-
minant of lentiviral pathogenicity (reviewed in [1]).
Infections with Nef-deleted strains of HIV-1 [2,3] or
SIVmac [4,5] result in limited disease progression in
humans and primates, respectively. The mechanisms by
which Nef enhances viral replication and pathogenicity
are unclear. A conserved feature of lentiviral nef genes is
the ability to enhance viral replication in freshly isolated
T cells that are infected and subsequently activated 2 to
5 days post-infection [6-11]. Under these conditions,
Nef+ viruses replicate with faster kinetics and peak at
higher levels (approximately 10-fold) than Nef- viruses.
In contrast, Nef has little or no effect on viral replica-
tion when T cells are activated prior to infection [7]. In
addition to enhancing viral replication in freshly isolated
T cells, Nef mediates downregulation of cell surface
receptors via interaction with the endocytic machinery.
Downmodulation of cell surface CD4 reduces interfer-
ence with viral envelope protein function [12,13]. Nef
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infected cells from CTL-mediated lysis [14,15]. Thus,
Nef-mediated effects on viral replication and pathogen-
esis may depend in part on its ability to enhance viral
replication in resting CD4+ T cells.
In resting T cells, HIV-1 viral replication is blocked at
a step prior to integration [16]. This restriction is over-
come when resting T cells are activated in response to
TCR stimulation [16-18]. Nef, which is expressed early
after infection in resting T cells [19], increases the num-
ber of T cells that activate NFAT and NF-Bp r o m o t e r
elements [20-23], secrete IL-2 [24], and express activa-
tion markers such as CD25 [25] and CD69 [26] in
response to TCR stimulation. Nef appears to lower the
threshold required for T cell activation, which may
increase the permissiveness of cells for productive
infection.
Previous studies suggest that Nef lowers the activation
threshold by interacting with components of the T cell
signaling machinery. Nef, via its SH3-binding P72xxP75
motif, associates with the Src Family kinases (SFKs) Fyn
[27] and Lck [28,29], which are proximal signaling mole-
cules activated immediately after TCR stimulation [30].
Nef also modulates the activation of downstream effec-
tors important for activation-induced cytoskeletal rear-
rangement including PAK2, CDC42, Vav [31,32], WASP
(Wiscott-Aldrich Syndrome protein) [33], and the Ezrin
Radixin Moesin (ERM) proteins Merlin [34] and cofilin
[35,36]. Nef associates with an activated form of PAK2
[37-39], a serine/threonine kinase important in T cell
activation and stress responses, in a multiprotein com-
plex found in detergent insoluble lipid rafts [40,41]. This
association is dependent on both CDC42 and Vav1 and,
possibly, b-PIX [42,43]. Functional links between SFKs
and PAK2 through Vav1 and CDC42 suggest Nef-PAK2
association may serve as a marker for a Nef-multipro-
tein signaling complex capable of altering T cell respon-
siveness via interaction with multiple host cell factors.
Despite extensive characterization of the molecular
determinants of Nef-PAK2 association, the importance
of this association for Nef function is still unclear.
The P72xxP75 motif of Nef is important for PAK2 and
SFK-association and contributes to MHC Class I down-
modulation [44,45]. Mutation of this motif also abro-
gates Nef-mediated enhancement of HIV-1 replication
[46,47] and T cell activation [20]. It is therefore difficult
to distinguish requirements for PAK2-association, SFK-
association, and MHC Class I downmodulation in Nef-
mediated enhancement of replication and T cell activa-
tion. We previously indentified residues important for
PAK2 association, but dispensable for CD4 or MHC
Class I downmodulation [48-50]. These determinants of
PAK2 association are located in a hydrophobic binding
surface formed by Clade B consensus positions 85, 89,
90, 186,187,188, and 191 [48]. Mutation of residue 191,
however, disrupts Nef association with Vav [31] and
SFKs [51]. Mutations at position 191 (F191H and
F191R) do not abrogate Nef-mediated enhancement of
NFAT activity in cells stimulated for 18 h with 1 μg/ml
PHA-P [52]. However, these mutants are unlikely to be
completely null for PAK2-association [48]. The role of
Nef-PAK2 association in Nef-mediated enhancement of
T cell activation and viral replication under various
levels of cell stimulation remains to be determined.
Therefore, further analyses of Nef variants bearing
mutations in the hydrophobic binding surface may pro-
vide insight into the biological role of the Nef-PAK2
complex in Nef-mediated enhancement of viral replica-
tion and T cell activation.
Here, we demonstrate that HIV-1 Nef mutants defec-
tive for the ability to associate with PAK2 are also defec-
tive for the ability to enhance viral replication in freshly
isolated primary T cells that are infected and subse-
quently activated by sub-maximal stimuli. Furthermore,
these Nef mutants are defective for the ability to
enhance responsiveness of Nef-expressing and bystander
primary T cells to activation induced by sub-maximal
stimuli. siRNA knockdown of PAK2 inhibited NFAT
activation both in the presence and absence of Nef, and
expression of a dominant-negative PAK2 mutant abro-
gated Nef-mediated enhancement of CD25 expression in
Jurkat cells. These findings suggest a model in which
Nef interacts with PAK2 to enhance the responsiveness
of infected cells and bystander cells to activating stimuli.
T h u s ,P A K 2i sl i k e l yt ob ei m p o r t a n tf o rN e f - m e d i a t e d
enhancement of viral replication and immune activation
in vivo.
Results
Nef association with activated PAK2 is not important for
enhancement of viral infectivity
To determine if the ability of Nef to associate with
PAK2 is important for its ability to enhance viral repli-
cation, we constructed a panel of NL4-3-based variants
containing nef genes with known abilities to associate
with PAK2. For these studies SF2 nef and the primary
nef genes 5C and 6I [34,48], which have been extensively
characterized for their ability to associate with PAK2,
were inserted into the pNL4-3 provirus (Figure 1A and
1B). A single amino acid mutant of 5C, 5C-3, disrupts
Nef-PAK2 association, but does not affect CD4 and
MHC Class I downmodulation [48]. The 5C-A72xxA75
mutation in the PXXP motif disrupts SH3 binding and
SFK association, PAK2 association, MHC Class I down-
modulation, and virion infectivity [53]. This pleiotropic
mutant was included because it was extensively charac-
terized in previous studies, and has been shown to dis-
rupt Nef-mediated enhancement of viral replication
Olivieri et al. Retrovirology 2011, 8:64
http://www.retrovirology.com/content/8/1/64
Page 2 of 17[54]. The primary nef gene 6I is defective for PAK2
association, and the 6I-1 mutant contains an L191F
mutation and possesses wild-type ability to associate
with activated PAK2 [48]. A ΔNef virus with a frame-
shift mutation in Nef introduced in an XhoI site within
Nef (ΔXhoI) was used as a negative control [7,55].
Nef enhances virion infectivity in single round infec-
t i o na s s a y s ,e v e nw h e nt h ev i r u si sp r o d u c e di nC D 4 -
negative cells [56]. Contradictory data exist regarding
whether or not abrogating the ability of Nef to associate
with PAK2 affects virion infectivity [52,57]. To deter-
mine if Nef proteins defective for PAK2-assocation dis-
play reduced enhancement of infectivity during a single
round of replication, we infected CD4+ CXCR4+MAGI
cells, which express b-galactosidase under the control of
the LTR, with equal amounts of virus normalized by RT
activity. At 36 h post-infection, SF2 Nef, 5C, 5C-3, 6I,
and 6I-1 viruses were 3- to 4-fold more infectious than
the ΔNef and 5C-A72xxA75 viruses (Figure 1C). To
achieve an equal MOI, a second infection was per-
formed with 5-fold more RT units of the ΔNef or 5C-
AxxA virus (Figure 1C and 1D). This dose resulted in
equivalent infectivity between ΔNef virus and the initial
dose of the SF2 Nef virus (Student’s t test p = 0.7), or
between 5C-AxxA virus and the initial dose of 5C virus
(p = 0.5). Equivalent MOIs were therefore achieved
using equal RT units of wild type and mutant Nef bear-
ing virus and 5-fold more RT units of the ΔNef or 5C-
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Figure 1 The ability of Nef to associate with PAK2 is not important for enhancing viral infectivity. A.K e yr e s i d u e si nt h ea m i n oa c i d
sequence of Nef variants used in this study. B. Primary Nefs and mutant Nefs were inserted into a modified NL4-3 provirus via a BamHI site in
Env and an artificial ClaI site in the viral LTR. SF2 Nef was inserted via an artificial MluI site at the start of Nef and the ClaI site. C and D. MAGI R5
+ cells were incubated with 5,000
3H cpm of RT activity of each viral variant for 6 h. At 36 h post-infection, the cells were fixed and stained for
b-galactosidase activity. Average percent of infected (b-galactosidase+) cells from triplicate infections +/standard errors of the mean (SEM) are
shown.
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is not important for Nef-mediated enhancement of
infectivity during a single round of viral replication.
Nef-mediated enhancement of viral replication is highly
dependent on the strength of activating stimuli
Although Nef expression increases the percentage of T
cells responding to activating stimuli, the levels of acti-
vation markers or activation-dependent transcription are
similar between Nef+ and Nef- cells [22,24]. Therefore,
Nef appears to reduce the threshold of stimulation
required for T cell activation [22,24]. To examine the
relationship between Nef-PAK2 association and HIV
replication in PBMC, we firsts o u g h tt oi d e n t i f yas u b -
maximal stimulus that induced measurable T cell activa-
tion and sustained viral replication, but did not activate
all cells. Previous reports describing effects of Nef on
HIV-1 replication used 3 days of stimulation with PHA-
P( 1μg/ml) [7], PHA-P (2 μg/ml) [6], or a-CD3/CD28-
coated beads [19] in the presence of IL-2 to stimulate T
cells or PBMC that were infected immediately after iso-
lation. Each of these stimuli was evaluated for their abil-
ity to influence Nef-mediated enhancement of
replication. IL-2 alone was also tested for the ability to
activate freshly isolated PBMC. Cultures were stained
for cell surface expression of CD3 and the activation
markers CD25 and HLA-DR. Median fluorescence
intensity (MFI) was calculated to define populations that
contain multiple peaks of CD25 and HLA-DR expres-
sion within the CD3+ population. Prior to activation,
PBMC cultures contained 8.3% CD25+ T cells (MFI
170) (data not shown). On day 3 post-activation, cul-
tures with IL-2 alone contained 11.9% CD25+ cells (MFI
160) and 11.7% HLA-DR+ T cells (MFI 129). CD25- and
HLA-DR-positive cells were more frequent in PBMC
cultures stimulated with a-CD3/CD28-coated beads
than in cultures stimulated with either dose of PHA-P
(Figure 2A). Cultures stimulated with 1 μg/ml PHA-P
contained the lowest percentage of CD25+ (70.4%) and
HLA-DR+ (35.7%) cells. Cultures stimulated with 2 μg/
ml PHA-P contained a similar frequency of CD25+ and
HLA-DR+ cells compared to cultures stimulated with a-
CD3/CD28 (95.1% CD25+ and 56.9% HLA-DR+ versus
98.9% CD25+ and 57.9% HLA-DR+, respectively). CD25
MFI was approximately 3-fold lower in cultures stimu-
lated with 1 μg / m lP H A - P( M F I5 , 5 7 9 )t h a ni nc u l t u r e s
stimulated with 2 μg/ml PHA-P (MFI 16,446), and 12-
fold lower than in cultures stimulated with a-CD3/
CD28-coated beads (MFI 65,178). HLA-DR MFI was 3-
fold lower in cultures stimulated with 1 μg/ml PHA-P
(MFI 414) than cultures stimulated with 2 μg/ml PHA-P
(MFI 1,132). In contrast to CD25 MFI, HLA-DR MFI
was only 3-fold lower in cultures stimulated with 1 μg/
ml PHA-P than in cultures stimulated with a-CD3/
CD28-coated beads (MFI 1,144) and was similar
between cultures stimulated with 2 μg/ml PHA-P and
a-CD3/CD28-coated beads. CD25 is an early activation
marker that is expressed at high levels 3 days post-acti-
vation; HLA-DR is upregulated at later time points [58].
CD25 MFI changed much more dynamically than %
CD25+ when comparing stimuli of different strengths,
in part reflecting changes in a CD25+ sub-population
that expresses high levels of CD25. Thus, these stimuli
provide three different levels of cellular activation,
reflected by robust differences in CD25 MFI, which can
be used to determine appropriate experimental condi-
tions for measuring the effect of Nef on HIV-1
replication.
To examine whether Nef-PAK2 association is impor-
tant for Nef-mediated enhancement of viral replication
in primary T cells, we then tested a panel of viruses for
their ability to replicate in freshly isolated PBMC under
each of the conditions described above. We used each
of these stimuli in the presence of IL-2 to activate
freshly isolated PBMC that were previously infected
with an equivalent infectious dose of virus. Viral replica-
tion was monitored by p24 ELISA of culture superna-
tants. In cultures stimulated with a-CD3/CD28 beads,
viruses expressing Nef proteins capable of associating
with activated PAK2 (SF2, 5C, and 6I-1) replicated at
similar levels compared to viruses expressing Nef pro-
teins defective for PAK2 association (5C-3, 5C-AxxA,
and 6I) or ΔNef virus (Figure 2B). At this strong level of
stimulation, there was no difference in levels of Nef+
and Nef- HIV-1 replication. When cultures were stimu-
lated with 2 μg/ml PHA-P, ΔNef virus replicated more
slowly than SF2 Nef virus, achieving peak levels of viral
replication 3 days later. Under this condition, wild-type
virus replicated to peak values that were 3-fold lower
compared to those seen when cultures were stimulated
with a-CD3/CD28 beads, and the 5C-AxxA virus repli-
cated to 2-fold lower peak values compared to the 5C
and 5C-3 viruses. No difference was observed between
the 5C and 5C-3 viruses, or the 6I-1 and 6I viruses. At
this intermediate level of stimulation, differences
between Nef+ and Nef- viruses were detected but Nef-
mediated enhancement of viral replication was consider-
ably less than the 10-fold effect previously reported
[7,9]. When 1 μg/ml PHA-P was used, wild-type virus
replicated to a peak value 3-fold lower than the levels
observed when 2 μg/ml PHA-P was used as a stimulus.
Under this condition, the ΔNef virus failed to replicate
to detectable levels (Figure 2B). CD25 MFI correlated
positively with peak p24 levels of wild-type SF2 virus
(Additional File 1, Figure S1A, p = 0.015, r = 0.898;
Spearman correlation), and negatively with Nef-
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Page 4 of 17mediated enhancement of replication (Additional File 2,
Figure S1B, p = 0.016, r = -0.892). In contrast, HLA-DR
MFI did not correlate with viral replication (p = 0.44) or
Nef-mediated enhancement of replication (p = 0.67).
Therefore, increased CD25 MFI after 3 days of stimula-
tion, rather than the % of CD25+ cells, was the best pre-
dictor of peak levels of viral replication and the ability of
Nef to enhance viral replication.
The ability of Nef to associate with activated PAK2
correlates with the ability to enhance HIV-1 replication in
freshly isolated PBMC
The low level of activation following stimulation with 1
μg/ml PHA-P (Figure 2B) provides an optimal window
to detect Nef-mediated enhancement of HIV-1 replica-
tion in freshly isolated PBMC. Under these experimental
conditions, the 5C virus replicated to peak levels ~5-fold
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Figure 2 Nef-mediated enhancement of replication is highly dependent on the strength of activating stimuli and the level of T cell
activation. A. Freshly-isolated PBMC were cultured in the presence of IL-2 (10 U/ml) alone or with either PHA-P (1 μg/ml), PHA-P (2 μg/ml), or
a-CD3/CD28 beads (1 bead per cell) for three days. On day 3, cells were stained with a-CD3-FITC and a-CD25-PE or a-CD3-FITC and a-HLA-DR-
PE or isotypic controls and analyzed by flow cytometry. %CD25+, %HLA-DR+, and CD25 and HLA-DR median fluorescence intensity of the CD3+
population is shown. Results are typical of three donors. B. Freshly isolated PBMC were infected with an equivalent MOI. Three days post-
infection cells were activated with IL-2 (10 U/ml) and either PHA-P (1 μg/ml), PHA-P (2 μg/ml), or a-CD3/CD28 beads (1 bead per cell) for three
days. Three days post-activation, the stimulation media was removed and replaced with IL-2 (10 U/ml)-containing media. p24 in culture
supernatants was monitored by ELISA.
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the 6I-1 virus replicated to peak levels 3-fold higher
than 6I and achieved peak levels of replication 3 days
earlier. Reduced replication of the 5C-AxxA virus is
consistent with previous studies [54]. 5C-3 and 6I
mutant viruses, which are defective for PAK2-associa-
tion, but functional for CD4 and MHC Class I down
modulation and infectivity enhancement, did not
enhance replication compared to ΔNef virus. These
results suggest that Nef-PAK2 association is important
for enhancing HIV-1 replication when freshly isolated T
cells are infected and sub-maximally activated.
Nef residues important for PAK2-association are also
important for enhancing T cell activation
Nef-mediated enhancement of T cell activation is a
potential mechanism by which Nef may enhance viral
replication [19,59]. Therefore, we sought to determine
whether Nef mutants defective for PAK2-association are
also defective for the ability to enhance T cell activation.
Previous reports have shown that Nef expression
enhances upregulation of CD25 [60] and activation of
NFAT and ILR promoter elements in response to CD3
stimulation in Jurkat cells [23]. Therefore, we first
examined the phenotype of Nef mutants defective for
PAK2 association in Jurkat E6.1 clones stably expressing
either NFAT-Luc or IL2R-Luc reporter constructs fol-
lowing infection with each Nef variant virus [23]. Pseu-
dotyping with VSV-G eliminates Nef-mediated
infectivity enhancement and enhances viral infectivity
compared to pseudotyping with HIV Env [61]. Infection
of MAGI cells with equal amounts of RT activity con-
firmed these prior findings. VSV-G pseudotyped viruses
infected 2-fold more cells compared to viruses expres-
sing only the HIV Env (Figure 1C vs. Figure 3A). As
expected, Nef expression did not alter the ability of
VSV-G pseudotyped virus to infect MAGI cells. There-
fore, VSV-G pseudotyped viruses were used to allow
equivalent, high-efficiency infection of the Jurkat NFAT-
Luc and Jurkat IL2R-Luc reporter cells.
To determine whether Nef-PAK2 association is impor-
tant for Nef-mediated enhancement of T cell activation,
we infected the NFAT-Luc and IL2R-Luc reporter cells
with an equal MOI of VSV-G pseudotyped virus. At 24
h post-infection, luciferase activities in unstimulated
cells were equivalent between mock-infected and HIV-
infected cultures irrespective of the Nef variant
expressed. After 4 h of stimulation with a-CD3/CD28-
coated beads, in contrast to the 72 h stimulation in Fig-
ure 2B, NFAT-Luc cells infected with SF2, 5C, and 6I-1
virus had 5-, 3.5-, and 4-fold higher levels of luciferase
activity than did ΔNef, 5C-3, and 6I-1, respectively. In
IL2R-Luc cells, SF2, 5C, and 6I-1 Nef had 2-, 2.5-, and
2-fold higher levels of luciferase activity than did ΔNef,
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Figure 3 The ability of Nef to associate with activated PAK2
correlates with the ability to enhance T cell activation. A. MAGI
R5+ cells were incubated for 6 h with 5,000
3H cpm of RT activity of
VSV-G pseudotyped virus. Infections and staining were performed as
in Figure 1B. Average percent of infected (b-galactosidase+) cells
from triplicate infections ± SEM are shown. B and C. 200,000
3H
cpm of RT activity of VSV-G pseudotyped virus were incubated
overnight with 10
6 Jurkat cells stably expressing NFAT-Luc (B)o r
IL2R-Luc (C). Infected cells were then incubated with 10
6 a-CD3/
CD28 beads for 4 h. Cells were lysed with passive lysis buffer. The
lysate was freeze/thawed once and luciferase activity was assayed
by luminescence. Average luciferase activity for triplicate samples ±
SEM is shown.
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Page 6 of 175C-3, and 6I-1, respectively (Figure 3B and 3C). After 8
h or 16 h of stimulation with a-CD3/CD28-coated
beads, wild-type Nef virus did not enhance cellular acti-
vation or NFAT-luc activity compared to Nef- or
mutant Nef virus unless theb e a dc o n c e n t r a t i o nw a s
reduced (Additional File 2, Figure S2 and Additional
File 3, Figure S3). Therefore, in the context of viral
infection, the ability of Nef to enhance NFAT and IL2
receptor promoter-driven luciferase activity following T
cell receptor stimulation correlates with its ability to
associate with activated PAK2 and to enhance viral
replication, and is dependent on the strength of the acti-
vating stimulus and the length of time the stimulus is
applied.
Nef residues important for PAK2-association are
important for enhancing activation of primary CD4 and
CD8 T cells when Nef is expressed in the absence of
other viral proteins
To determine if the correlation between Nef-PAK2 asso-
ciation and Nef-mediated enhancement of T cell activa-
tion (Figure 3) exists when nef i st h eo n l yv i r a lg e n e
expressed, a lentiviral expression vector, pHAGE, was
used to transduce nef genes under the control of the full
EF1a promoter in PBMC. This vector contains an IRES
element at the 3’ end of the nef gene driving expression
of the GFP variant zsGreen. Lentiviral vectors were
packaged with HIV gag and pol and pseudotyped with
the CXCR4-tropic HIV-1 envelope HXB2. At 72 h post-
transduction, transduced unstimulated PBMC were
incubated for 3 days with 10 U/ml IL-2 with or without
1 μg/ml PHA-P. After stimulation, cell surface CD3,
CD8, CD25, and zsGreen expression was determined by
FACS analysis (Figure 4A). CD4 T cells exposed to no
vector (Mock) were used to set the zsGreen+ gate. 44%,
47%, and 50% of CD4 T cells were zsGreen+ when
transduced by vectors expressing 6I-1 Nef, 6I Nef, and
empty vector, respectively (Figure 4B). In the presence
of IL-2 alone, 8-12% of CD4 T cells expressed CD25
a n d<1 %o fC D 8Tc e l l se x p r e s s e dC D 2 5( F i g u r e4 D ,
left panel). No significant difference was observed
between 6I-1 and 6I, vector, and mock in Nef+ (zsGreen
+) CD4 T cells or CD8 T cells. Cultures transduced
with 6I-1 Nef contained 1.2- and 1.1-fold more CD25+
Nef-(zsGreen-) CD4 T cells than cultures transduced
with 6I Nef, or empty vector, respectively (p = 0.02 and
0.01). Following 3 days of 1 μg/ml PHA-P stimulation,
cultures transduced with 6I-1 Nef contained 1.14- and
1.17-fold more CD25+ Nef+(zsGreen+) CD4 T cells
compared to those transduced with 6I or empty vector
(p = 0.005 and 0.02, respectively), 1.3-, 1.5-, and 1.2-fold
more CD25+Nef-(zsGreen-) CD4 T cells compared to
those transduced with 6I Nef, empty vector, or mock
transduced (p = 0.002, 0.0002, and 0.01, respectively),
and 1.3-, 1.4-, and 1.4-fold more CD25+ CD8 T cells
compared to those transduced with 6I, empty vector or
mock transduced, respectively (p = 0.002, 0.017, and
0.01). Additionally, in cultures transduced with 6I-1 Nef
+(zsGreen+) CD4 T cells expressed 1.30- and 1.31-fold
higher CD25 MFI compared to cultures transduced with
6I or empty vector (p = 0.025 and 0.034, respectively),
CD25+Nef-(zsGreen-) CD4 T cells expressed 1.5-, 1.3-
and 1.3-fold higher CD25 MFI compared to those trans-
duced with 6I, empty vector, or mock transduced (p =
0.006, 0.024, and 0.02, respectively), and CD8 T cells
expressed 1.3-, 1.4-, and 1.4-fold higher CD25 MFI com-
pared to those transduced with 6I, empty vector, or
mock transduced, respectively (p = 0.005, 0.017, and
0.01). Nef-mediated enhancement of cellular activation
may have been reduced in zsGreen+ cells because lenti-
viral transduction likely occurred in cells that were
already activated, or partially activated. After 3 days of
stimulation with 1 μg/ml PHA-P in the presence of IL-
2, Nef enhances cellular activation of transduced and
bystander CD4 and CD8 T cells in a manner that is
dependent on Nef-PAK2 association. This effect, albeit
modest, is significant for two measures of T cell activa-
tion (% CD25+ and CD25 MFI) in 3 different T cell
populations (Nef+ CD4+, Nef-CD4+, Nef-CD8+). Thus,
Nef may increase the pool of bystander T cells permis-
sive for replication.
T cell activation is dependent on PAK2 both in the
presence and absence of Nef
To determine the requirement for PAK2 in Nef-
mediated enhancement of T cell activation, we transi-
ently transfected Jurkat NFAT-Luc cells with siRNA tar-
geting PAK2 and reduced PAK2 expression by ~2-fold
as determined by Western blotting (Figure 5A).
Untransfected cells or cells transfected with 10 pmol
control siRNA or PAK2 targeting siRNA were infected
with VSV-G pseudotyped HIV expressing the indicated
Nef as described above (Figure 3) and then stimulated
24 h post-infection with a-CD3/CD28 beads for 4 h. No
difference in NFAT-Luc activity was observed between
unstimulated cultures, regardless of viral infection or
siRNA transfection (Figure 5B). Following a-CD3/CD28
stimulation, Jurkat cells expressing 5C or 6I-1 Nef had
~2.5 - 2.7-fold higher levels of NFAT-Luc activity com-
pared to cells expressing the ΔNef control in cells trans-
fected with control siRNA. Transfection with PAK2
siRNA reduced NFAT-Luc activity by 80, 85, 82, and
83% for uninfected, ΔNef, 5C, and 6I-1-expressing cells,
respectively. Thus, NFAT activity in stimulated Jurkat
cells is dependent on PAK2 both in the presence and
absence of Nef.
As a complementary approach to determine the role
of PAK2 in Nef-mediated enhancement of T cell
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sing FLAG-tagged PAK2 K278R (PAK2 DN), a domi-
nant negative mutant. First, parental E6.1 cells and
PAK2 DN cells were infected with Nef-bearing pHAGE-
IRES-zsGreen vectors pseudotyped with VSV-G. Two
days post-transduction, PAK2 K278R complexes were
immunoprecipitated with agarose bound FLAG-antibo-
dies and analyzed by SDS-PAGE/Western blot for PAK2
K278R expression and co-precipitation of Nef (Figure
6A). PAK2 K278R-FLAG expression in PAK2 DN cells
was confirmed by western blotting with rabbit anti-
PAK2. PAK2 K278R co-immunoprecipitated SF2 and 5C
Nef, whereas co-immunoprecipitation of 5C-3 and 5C-
AxxA Nef was markedly reduced compared to 5C Nef.
To examine the effects of the dominant negative PAK2
mutant on Nef-mediated enhancement of T cell activa-
tion, cells were stimulated with 1 μg/ml PHA-P for 18
h, and then cell surface CD25 and zsGreen expression
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Figure 4 Residues important for PAK2-association are important for enhancing T cell activation when Nef is expressed alone.H X B 2
pseudotyped lentiviral particles containing pHAGE-EF1a-Nef-IRES-zsGreen genomes were used to transduce freshly isolated PBMC. Three days
post-transduction, the cells were stimulated with PHA-P (1 μg/ml) in the presence of 10 U/ml IL-2 for an additional 3 days. Replicate cultures
contained 10 U/ml IL-2 alone. All cultures were then stained with a-CD3-PE-Cy5.5, CD8-PE, and CD25-APC-Cy7. Cell surface markers and zsGreen
expression were monitored by flow cytometry. A. CD3 and CD8 expression define CD8 T cell (upper right quadrant) and CD4 T cell (lower right
quadrant) populations. CD8 T cells were analyzed directly for CD25 expression. CD4 T cells were analyzed for zsGreen expression in B. B. zsGreen
expression analysis of CD4 T cells. Transduced (Nef+ zsGreen+) and untransduced (Nef- zsGreen-) populations were defined for further analysis in
C. Open histogram is the mock transduction. Shaded histogram is the sample transduced with the empty vector. C. CD25 expression in
indicated populations. Total CD8 T cell population is shown in the upper panel. Nef+ (zsGreen+) populations are shown in the middle panel.
Nef- (zsGreen-) populations are shown in the bottom panel. Percent CD25+ and CD25 MFI of the entire population is shown above the
histogram. Representative plots for three samples are shown. D. The average % CD25 positive or CD25 MFI ± standard deviation (SD) of triplicate
cultures is shown for cultures with 10 U/ml IL-2 alone (left panel) or 1 μg/ml PHA-P with 10 U/ml IL-2. *p < 0.05 ** and p < 0.005 (Student’st -
test).
Olivieri et al. Retrovirology 2011, 8:64
http://www.retrovirology.com/content/8/1/64
Page 8 of 17were determined via flow cytometry. In cells transduced
with empty vector, CD25 MFI in Jurkat PAK2 DN cells
was reduced by 39% compared to parental E6.1 cells
(Figure 6B and 6C) (p = 0.0005), indicating that T cell
activation is dependent on PAK2 in the absence of Nef.
In contrast to Jurkat PAK2 DN cells, parental E6.1 cells
transduced with SF2 and 5C Nef (zsGreen+) expressed
1.2- and 1.3-fold higher CD25 MFI (p = 0.0062 and
0.0005, respectively) (Figure 6B and 6C), whereas the
5C-AxxA Nef mutant had no significant effect on CD25
MFI. In Jurkat PAK2 DN cells, SF2 and 5C Nef-
mediated enhancement of CD25 expression was reduced
4-fold or abolished, respectively (Figure 6B and 6C). No
significant difference was observed between SF2, 5C,
and 5C-AxxA Nef-expressing PAK2 DN cells compared
to cells expressing the vector control (p = 0.4169,
0.1703, and 0.5304, respectively). Therefore, experiments
using a dominant negative PAK2 mutant suggest that
SF2 and 5C Nef-mediated enhancement of T cell activa-
tion is dependent on PAK2.
To confirm that the ability of SF2, 5C, 5C-3, 5C-
AxxA, 6I-1 and 6I to associate with PAK2 correlates
with the previously reported abilities of these Nefs to
associate [48], or not, with activated PAK2 as deter-
mined by in vitro kinase assays, we transfected 293T
cells with plasmids for HA-tagged Nef, CDC42 V12, and
FLAG-tagged PAK2 K278R. Two days post-transfection,
complexes containing PAK2 K278R were immunopreci-
pitated with agarose bound FLAG-antibodies and ana-
lyzed by SDS-PAGE/Western blot for co-
immunoprecipitation (Figure 7). Co-immunoprecipitated
Nef was normalized to the amount of input Nef (Figure
7). Despite differences in expression levels between SF2,
5C, and 6I-1 wild-type Nefs, each wild-type Nef and the
corresponding mutants were expressed at similar levels.
Compared to 5C Nef, the ability of the 5C-3 and 5C-
AxxA mutants to associate with PAK2 was reduced
(Figure 7). Compared to 6I-1 Nef, the ability of the 6I
mutant to associate with PAK2 was reduced (Figure 7).
Thus, in both 293T cells and Jurkat cells, the ability of
wild-type and mutant Nefs to associate with PAK2 in
co-precipitation assays correlates with their previously
reported abilities to associate with activated PAK2
demonstrated by in vitro kinase activities [48] and with
their ability to enhance T cell activation (Figure 3 and
4) and HIV replication (Figure 2).
Discussion
Here, we show that the ability of Nef to associate with
activated PAK2 is important for its ability to enhance
HIV replication in freshly isolated T cells. Mutations at
positions 89 and 191, which disrupt PAK2 association,
rendered Nef defective for the ability to enhance cellular
activation and viral replication in freshly isolated T cells,
but not the ability to enhance viral infectivity or down-
modulate CD4 and MHC Class I [48]. As expected and
consistent with other reports [62,63], by targeted siRNA
knockdown we show that PAK2 is important not only
for Nef-mediated enhancement of T cell activation but
also for activation of T cells in the absence of Nef (Fig-
ure 5). We also show that Nef-mediated enhancement
of T cell activation is abrogated in the presence of a
dominant negative PAK2 mutant (Figure 6). The ability
of wild-type or mutant Nefs to enhance T cell activation
correlated with their ability to associate with PAK2 in
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Figure 5 siRNA knockdown of PAK2 in Jurkat cells reduces
NFAT activation induced by anti-CD3/CD28 stimulation
whether or not Nef is present. A. Jurkat NFAT-Luc cells were
transfected with 2 or 10 pmol of PAK2 siRNA or non-targeting
siRNA control pool. Three days later, cells were lysed in 1% NP-40
lysis buffer and analyzed by SDS-PAGE/Western blot for PAK2 and b-
tubulin expression. B. 200,000
3H cpm of RT activity of the indicated
VSV-G pseudotyped virus was incubated overnight with 10
6 NFAT-
Luc cells transfected with 10 pmol of the indicated siRNA. Infected
cells were then incubated with 10
6 a-CD3/CD28 beads for 4 h. Cells
were lysed with passive lysis buffer. The lysate was freeze/thawed
once and luciferase activity was assayed by luminescence. Average
luciferase activity for triplicate samples ± SEM is shown.
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Figure 6 Expression of a dominant negative PAK2 mutant inhibits Nef-mediated enhancement of CD25 expression in Jurkat cells
stimulated by PHA-P (1 μg/ml). A and B. Jurkat E6.1 cells were transfected with pCDNA3.1 FLAG-PAK2 K278R (PAK2 DN) and passaged in 1
mg/ml G418 for 15 days. 1.5 × 10
6 parental E6.1 cells and PAK2 DN cells were transduced with 50,000 cpm of RT activity of the indicated pHAGE
Nef-IRES-zsGreen vectors. A. At 48 h post-transduction, cells were lysed in 1% NP-40 lysis buffer. 10 μl of anti-FLAG agarose conjugate beads
were used to immunoprecipitate FLAG-PAK2 from 1 mg of lysate. Bead bound proteins were eluted in 2X SDS sample buffer, and analyzed by
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6A and 7). Together, these data are consistent with a
model in which enhancement of T cell activation and
HIV replication occur through related mechanisms
involving Nef association with PAK2, most likely within
a multiprotein complex.
Previous studies suggest that Nef enhances HIV repli-
cation by reducing the threshold of cellular activation
[19,24]. Consistent with this model, we found that Nef-
dependent enhancement of viral replication in T cells
stimulated after infection is highly dependent on the
strength of activating stimuli. The greatest differences in
levels of replication between Nef+ and Nef- viruses were
observed in cultures sub-maximally stimulated with 1
μg/ml PHA-P for 72 h (Figure 2A). The strength of the
activating stimulus correlated inversely with Nef-
mediated enhancement of HIV-1 replication (Additional
File 1, Figure S1). Reducing the concentration of a-
CD3/CD28 beads (Additional File 2, Figure S2), or
shortening the duration of stimulation (Additional File
3, Figure S3 and Figure 3, Figure 4, and [22]), is
required to detect Nef-mediated enhancement of cellular
activation. These findings imply that sub-maximal sti-
mulation, regardless of whether PHA-P or a-CD3/CD28
beads are used, is required to detect Nef-mediated
enhancement of viral replication and T cell activation.
Excluding IL-2 from the cell culture media resulted in
only 1.6% viable cells. Thus, we cannot exclude the pos-
sibility that IL-2 alone increased the number of cells
permissive for infection [64]. Importantly, these findings
demonstrate that Nef-mediated enhancement of replica-
tion and activation can be masked when strong stimuli
are used to induce cellular activation.
Nef may enhance HIV replication via several distinct
mechanisms that are not mutually exclusive. Nef
enhances viral replication in freshly isolated PBMC,
which contains a small fraction of activated or partially
activated T cells [6,7,9]. Nef expression can enhance the
promoter activity of the LTR [21] and specific host cell
genes [24,59,65] via mechanisms that may involve upre-
gulation of tat-SF1, U1 SNRNP,a n dIRF-2 mRNAs [59]
and enhancement of NFAT activity [20,23], thereby
increasing the amount of viral particles produced per
cell. As we and others have demonstrated, Nef interac-
tion with cell signaling machinery in unstimulated T
cells may render them permissive for high levels of pro-
ductive infection upon subsequent stimulation by redu-
cing the threshold required for cellular activation. As
such, the inverse correlation between Nef-mediated
enhancement of replication and the strength of cellular
stimulation (Additional File 1, Figure S1B) is likely to
reflect both an increase in the number of permissive
cells and increased p24 production per cell. We found
that activation of bystander CD4 and CD8 T cells is
enhanced in the presence of Nef expression cells.
Bystander activation may be important for HIV replica-
tion in vivo, as this would be expected to increase the
pool of target cells permissive for productive infection
and to contribute to activation induced cell death of
CD4 and CD8 T cells associated with HIV infection.
Therefore, Nef-mediated enhancement of T cell activa-
tion may positively influence viral replication and patho-
genesis via several distinct mechanisms.
The role of PAK2 in Nef-mediated enhancement of T
cell activation is unclear because PAK2 activation is
dependent on several cellular factors. The results of
experiments using PAK2 siRNA knock-down and a
dominant negative PAK2 mutant (Figure 5 and 6) imply
that PAK2 itself, and/or molecules that interact with
PAK2, are important for Nef-mediated enhancement of
T cell activation. For example, activation of PAK2 is
dependent on binding of CDC42-GTP to the PAK2
CRIB (Cdc42- and Rac-interactive binding) domain.
CDC42 binds PAK2 only in its GTP bound state, which
occurs after guanine nucleotide exchange factors (GEF),
such as Vav, induce exchange of GDP for GTP. Nef
may therefore interact with upstream signaling mole-
cules such as SFKs, Vav1, or CDC42 in order to associ-
ate with activated PAK2. Identifying binding partners of
Nef important for PAK2-association may help to identify
other host cell factors necessary for Nef-mediated
enhancement of T cell activation and viral replication.
Previous reports evaluating the contribution of Nef-
PAK2 association to HIV replication reached conclu-
sions that differ from our own. One study demonstrated
that siRNA knockdown of PAK2 was not important for
infection of HeLa and Jurkat cells [66]. However, freshly


 	















	


Figure 7 Nef residues important for enhancement of viral
replication and cell activation are also important for
association of Nef with PAK2 in co-precipitation assays. A. 293T
cells were transfected with 0.5 μg pCR3.1 Nef-HA or empty vector,
0.5 μg pCDNA.31 FLAG-PAK2 K278R, and 0.5 μg CDC42 V12 in 6-
well plates. 48 h post-transfection, cells were lysed in 1ml 1% NP-40
lysis buffer. 10 μl of anti-FLAG agarose conjugate beads were used
to immunoprecipitate FLAG-PAK2 from 1 mg of lysate. Bead bound
proteins were eluted in 2X SDS sample buffer, separated on a 12%
polyacrylamide gel, and transferred to PVDF. Expression was
detected by Western blot.
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vant cell-type for studies of Nef function. Furthermore,
HeLa and Jurkat cells do not require activation by exter-
nal stimuli to become permissive for HIV replication. A
second study used experimental conditions that may
mask Nef-mediated enhancement of T cell activation
[52]. Schindler et al. [52] incubated Jurkat NFAT-Luc
reporter cells with PHA for 16 h. However, we found
that extending the time of stimulation with a-CD3/
CD28 coated beads from 4 to 8 h abrogated Nef-
mediated enhancement of NFAT-Luc activity (Figure 3
and Additional File 3, Figure S3) and extending the time
of stimulation with 1 μg / m lP H A - Pf r o m1 8t o2 4h
abrogated Nef-mediated enhancement of CD25 upregu-
lation in Jurkat E6.1 cells (Additional File 4, Figure S4).
Thus, our identification of sp e c i f i ca s s a yc o n d i t i o n si n
which Nef expression enhances T cell activation and
HIV replication sheds light on potential explanations for
different results among studies that examined the
importance of PAK2 for Nef-mediated enhancement of
HIV replication.
Significant controversy surrounds the issue of whether
or not Nef-PAK2 association contributes to SIV patho-
genesis. In two studies, rhesus macaques infected with
SIV mutated in the PxxP domain of Nef did not develop
high viral loads until reversion of the mutations
occurred [45,67]. In contrast, one study demonstrated
that SIVmac239 containing the same PxxP mutation
began to develop high viral loads 4 days prior to detec-
tion of reversion to wild-type [68]. The inconsistency of
these findings may relate to certain limitations of the
SIV model. Because of rapid disease progression, SIV-
mac239 infection of macaques may not be an accurate
model for the chronic phase of HIV infection. PAK2
activation may be more important during chronic infec-
tion, when immune activation is lower and infected T
cells are more likely to be resting, than during acute
infection and late stage disease, when T cells have
higher levels of activation. Indeed, lymphoid-derived
Nefs in late stages of disease acquire rare, non-conserva-
tive mutations at positions critical for PAK2-association
potentially abrogating the ability of Nef to associate with
PAK2 [69]. Accordingly, Nef-PAK2 association may be
important for pathogenesis in vivo in the same context
for which it is important for enhancing replication in
vitro: when infected T cells are resting.
An important finding in our study relates to technical
issues that may help to explain major discrepancies
between results from different groups regarding HIV
replication in freshly isolated PBMC. Three technical
points were critical for reproducibility of a strong Nef-
dependent phenotype in freshly isolated PBMC: 1) using
PBMC isolated from fresh blood instead of cryopre-
served PBMC; 2) using highly purified PBMC free of
platelet contamination; and 3) using pooled human A/B
s e r u md e t e r m i n e dt ob ef r e eo fe n d o t o x i n .O u rp r e l i -
minary studies comparing different methods for this
assay suggested that PBMC derived from cryopreserved
rather than fresh samples, as well as PBMC containing
even low levels of contaminating platelets, are more
“activated” than PBMC obtained from fresh blood or
isolated free of platelet contamination. Thus, assays that
use cryopreserved PBMC or are conducted in the pre-
sence of contaminating platelets are not representative
of results in “resting” PBMC. Platelets can release
RANTES and other soluble factors that can activate
PBMC, so platelet-free PBMC preparations are critical
for assays that depend on a “resting” PBMC phenotype.
We observed that fetal bovine serum (FBS) enhances
survival of activated PBMC compared to pooled human
A/B serum, thereby increasing the number of activated
cells and reducing the percentage of resting cells. Thus,
stimulation in the presence of FBS may result in stron-
ger cell stimulation than delivering the same stimulus in
the presence of human A/B serum. We have shown that
the ability of Nef to enhance replication in freshly iso-
lated PBMC is highly dependent on the strength and
duration of stimulation. Therefore, confounding factors
that enhance the strength of stimulation may mask cer-
tain Nef phenotypes. For example, the presence of endo-
toxin in some serum preparations may alter the cytokine
profile of PBMC. In summary, using freshly isolated
rather than cryopreserved PBMC and reducing PBMC
activation by factors such as platelet contamination and
serum endotoxin, and determining the strength and
duration of stimulation required for sub-maximal stimu-
lation are critical in order to achieve consistent effects
of Nef on HIV-1 replication in resting T cells from a
given donor.
Conclusion
HIV-1 Nef-mediated enhancement of T cell activation
and viral replication in T cells is dependent on PAK2
and the strength of T cell activating stimuli, and corre-
lates with the ability of Nef to associate with PAK2.
Nef-mediated enhancement of T cell activation may
increase the number of infected cells able to produce
progeny virus along with the amount of virus produced
per cell. Additionally, Nef increases the number of unin-
fected bystander cells permissive for viral replication in
a manner that is dependent on Nef residues important
for PAK2 association. Two structural domains appear to
govern the ability of Nef to enhance activation of
infected and uninfected cells: the PxxP motif, which
interacts with SH3 domains, and the hydrophobic bind-
ing surface formed between residues 89 and 191, which
may interact with an unknown binding partner [48].
Future analysis of the Nef-PAK2 interaction will
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domain-containing cellular factors that influence both
PAK2 association and T cell activation. This interaction
is an attractive potential therapeutic target because an
inhibitor that blocks the ability of Nef to interact with
host cell factors important for enhancement of HIV-1
replication and T cell activation would be expected to
reduce viral replication and, similar to infections with
Nef-deleted strains of HIV and SIV, postpone the onset
of AIDS.
Materials and methods
Proviral Construction
Primary Nefs and their mutants cloned into pCR3.1
were digested with BamHI and ClaI and inserted into
the corresponding sites in a modified pNL4-3 provirus
[70]. SF2 Nef was inserted via MluI and ClaI sites. Nef-
negative pNL4-3 ΔXhoI was provided by Damian Pur-
cell. Viral stocks were produced by CaPO4 transfection
o f3×1 0
6 293T cells in a 10 cm plate with 10 ug of
provirus and, where indicated, 1 ug of pVSV-G. Viral
stocks were assayed for reverse transcriptase activity as
described previously [71].
Lentiviral Vector Construction and Production
pCR3.1 Nef plasmids were amplified with primers
5’AAAAGCGGCCGCCACCATGGGTGGCAAGTGGT-
CAAAA3’ and 5’AAGGATCCTCATGAAGCG-
TAATCTGGCAC 3’, which add a NotI site and a Kozak
sequence to the 5’ end of Nef and a BamHI site to the
3’ end of Nef. Nef genes were inserted into pHAGE
fEF1a-IRES-zsGreen which was kindly provided by the
Harvard Gene Therapy Initiative [72]. 3.5 μgo fp H A G E
vector,3.5 μg of the packaging construct pDR89.1 [73],
and 1 μg of pVSV-G were transfected by lipid transfec-
tion (LipoD293T, Signagen) into 5.5 × 10
6 293T cells
plated 24 h prior in a 10-cm tissue culture plate. Med-
ium was changed at 18 h and vector containing super-
natants were harvested after an additional 24 hours.
Vector containing supernatants were assayed for RT
activity as described previously [71].
PBMC Isolation and Infection
Healthy HIV-/HCV- donor blood provided by Research
Blood Components (Boston, MA) was collected into
EDTA vacutainer tubes. The protocol for obtaining
blood was approved by the Dana-Farber Cancer Institute
IRB. After collection, 10 mls of fresh blood were diluted
1:1 with PBS and layered over 15 ml Ficoll Histopaque
1077 (Sigma) and spun at 2000 × g for 20 min at room
temperature. 5 mls of PBMC containing serum were
collected at the interface and diluted with 20 mls of
PBS. The diluted cells were pelleted at 1000 × g for 10
min at 4°C, resuspended in 10 mls of PBS, and pelleted
again at 1000 × g for 10 min. The cell pellet was resus-
pended in 10 mls of RPMI-1640 (Invitrogen) and pel-
leted at 1000 × g for 10 min. Cells were counted and
r e s u s p e n d e da t2×1 0
6/ml in RPMI-1640 with 10%
pooled Human A/B sera (Gemini) and 5 U/ml penicil-
lin/streptomycin. Infections contained 8 X10
5 cells in
800 μlw i t h4 , 0 0 0
3Hc p mo fR Ta c t i v i t yf o rS F 2 ,5 C ,
5C-3, 6I-1, and 6I Nef-bearing proviruses or 12,000 and
16,000
3H cpm of RT activity for pNL4-3 ΔXhoI and
5C-AxxA, respectively. Freshly-isolated PBMC were
incubated overnight in a 15 ml conical tube at 37°C and
washed twice in PBS the following day. Cells were resus-
pended in 800 μl of media and incubated for 2 days. On
day 3 post-infection, cells were pelleted and resuspended
in media containing 10 u/ml IL-2 with either 1 ug/ml
PHA-P (Sigma), 2 ug/ml PHA-P, or a-CD3/CD28 beads
(Invitrogen) at a bead-to-cell ratio of 1:1. Three days
post-activation (day 6 post-infection), infected cultures
were washed twice and returned to media containing 10
u/ml IL-2. Replicate samples of activated PBMC were
analyzed for levels of cell activation as described below.
Two hundred μl of resuspended cultures were plated in
triplicate in a 96-well U-bottom plate. Every three or
four days, 0.5 volume of media was removed and saved,
and replaced with 0.5 volume fresh media to compen-
sate for evaporation. Viral replication was measured by
p24 ELISA (Perkin-Elmer) of culture supernatants.
FACS analysis
2×1 0
5 PBMC were washed twice with cold PBS con-
taining 2 mM EDTA (PBS-E) and resuspended in 200 μl
of PBS-E containing 2% FBS with 5 μlo fC D 3 - F I T C
(BD Pharmingen) and 5 μl of CD25-PE (BD Pharmin-
gen). Cells and antibody were incubated at 4°C for 45
min. Cells were washed twice with PBS-E and resus-
pended in PBS and analyzed on a BD FACSCanto II cell
cytometer. FACS analysis was done using BD FACSDiva
software.
MAGI Infection
4×1 0
4 MAGI indicator cells (NIH AIDS Reagent Repo-
sitory) were plated in a 12-well plate in selection media
(Dulbecco’s modified Eagle’s medium (DMEM; Invitro-
gen) supplemented with 10% fetal calf serum, 5 U/ml
pen/strep plus 0.2 mg/ml G418 (at an active concentra-
tion of 700 μg per mg), 50 U/ml hygromycin, and 1 μg/
ml puromycin. Twenty-four hours later, selective media
w a sr e m o v e df r o mt h r e ew e l l sa tat i m ea n dr e p l a c e d
with 5000 cpm of RT activity in 300 μlo fD M E Mp l u s
20 μg/ml of DEAE-Dextran. Cells and virus were incu-
bated for 6 h at 37°C. Cells were washed three times
with PBS and incubated for 36 h at 37°C in 1 ml of
DMEM without selection. Cells were washed once and
fixed with 1 ml of 1% formaldehyde, 0.2% glutaraldehyde
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Page 13 of 17in PBS for 5 min. The cells were washed twice with PBS
and incubated with PBS containing 4 mM potassium
ferrocyanide, 4 mM potassium fericcyanide, 2 mM
Mg2Cl, and 0.4 mg/ml X-gal for 50 min at 37°C in a dry
incubator. Three random fields from each of three tripli-
cate wells were counted for each infection. Percent
Infected cells = b-galactosidase + cells (blue cells) in
field/total number of cells in field × 100%.
Luciferase Reporter Assay
IL2R-Luc and NFAT-Luc Jurkat E6.1 cells were kindly
provided by Dr. Michel Tremblay, University of Laval,
Montreal, Canada [23]. 5 × 10
5 cells were plated in 1 ml
of non-selective media with 200,000 cpm of RT of VSV-
G pseudotyped vectors and incubated for 18 h. Cells
were washed twice with PBS and resuspended in 1 ml of
media containing 5 × 10
5 a-CD3/CD28 beads (Invitro-
gen). After 6 h of incubation at 37°C, the cells were pel-
leted, washed twice with PBS and resuspended in 200 μl
Passive Lysis Buffer (Stratagene), incubated at room
temperature for 15 min, and subjected to one round of
freeze/thaw. Twenty μl of lysate was added to wells of a
96-well white-wall black plate. 100 μl Stratagene Lucifer-
ase Assay buffer mixture was added and luciferase activ-
ity was read on a Bethold Centro LB 960 luminometer.
Lentiviral transduction
2×1 0
6 freshly-isolated PBMC were incubated in 1 ml
of media containing 750,000
3H cpm of RT activity in
the presence of 8 μg/ml polybrene. Cells were spun for
2 h at 2,000 RPM at 30°C, incubated overnight. Media
was removed and 10% glycerol in PBS solution was
added and immediately washed twice with PBS. 2 × 10
5
cells were added to a U-bottom, 96-well plate in media
containing 10 U/ml IL-2 for three days. Fresh media
containing 1 μg/ml PHA-P and 10 U/ml IL-2 or IL-2
alone were added to the cultures and incubated for 72
h. Cells were then washed twice with cold PBS-E and
resuspended in 200 μl PBS-E FBS containing 1 μlo f
CD25-APC-Cy7 (BD Pharmingen), 5 μlC D 8 - P E ,a n d5
μl CD3-PE Cy5.5. Cells were incubated for 45 min at 4°
C, washed twice with PBS-E, and resuspended in PBS.
Acquisition and analysis were done with a BD FACS-
Canto cell cytometer using BD FACSDiva software. FSC
and SSC were used to define a lymphocyte population
consistent between all samples.
siRNA transfection of Jurkat E6.1 cells
5×1 0
6 Jurkat E6.1 cells were nucleofected in 100 μl
AMAXA Solution V in program S-18 with 10 or 2 pmol
of siRNA targeting PAK2 (SmartPool, Dharmacon) or
non-targeting control siRNA (Dharmacon). Cells were
cultured for 48 h in 10% FBS RPMI supplemented with
1X GlutaMax (Invitrogen), prior to infection or 66 h
prior to SDS-PAGE/Western blot analysis for PAK2
expression. SDS-PAGE/Western blotting was carried out
as described above. Blots were probed with anti-b-tubu-
lin (1:1000, Sigma-Aldrich) and rabbit anti-PAK2
(1:1000, Cell Signaling).
Generation of Jurkat cells stably expressing a dominant
negative PAK2 mutant
10
6 Jurkat E6.1 cells were nucleofected in 100 μl
AMAXA Solution V in program S-18 with 1 μgo f
pCDNA3.1FLAG-PAK2 K278R. Cells were passaged in 1
mg/ml G418 10% FBS RPMI supplemented with 1X
GlutaMax (Invitrogen) for 15 days. Expression of the
FLAG-tagged PAK2 mutant was confirmed by Western
blot with anti-FLAG. 3 × 10
6 parental control or PAK2
DN-expressing Jurkat E6.1 cells were transduced with
25,000 cpm of RT activity of pHAGE-Nef-IRES-zsGreen
vectors. 8 h post-transduction, cells were washed twice
and stimulated with 1 μg/ml PHA-P for 18 h, following
which cells were stained with CD25 APC-Cy7 and ana-
lyzed by flow cytometry for zsGreen and CD25
expression.
Nef-PAK2 co-immunoprecipitation in Jurkat E6.1 PAK2 DN
cells
3×1 0
6 Jurkat E6.1 parental or Jurkat E6.1 PAK2 DN
cells were transduced with 600,000 cpm of RT activity
of VSV-G pseudotyped pHAGE Nef-IRES-zsGreen vec-
tors. Cells were incubated for 16 h with lentiviral vec-
tors and then washed twice with PBS. After 48 h in
culture, cells were washed twice with PBS and lysed in 1
ml 1% NP-40 lysis buffer. Immunocomplexes were iso-
lated and analyzed as described below.
Nef-PAK2 co-immunoprecipitation in 293T cells
4.5 × 10
5 293T cells were seeded into 6-well plates 24 h
prior to transfection. 0.5 μg pCR3.1 Nef-HA or empty
vector, 0.5 μg pCDNA.31 FLAG-PAK2 K278R, and 0.5
μg CDC42 V12 in 75 μl serum-free DMEM were mixed
with 3 ul GenJet (SignaGen) in 75 μls e r u m - f r e e
DMEM, incubated for 15 minutes, and added to culture
wells. 48 h post-transfection, cells were washed twice
with PBS and lysed in 1 ml 1% NP-40, 50 mM Tris, 150
mM NaCl, pH 8.0 lysis buffer containing Compete Pro-
tease Inhibitor (Roche) and PhosphoStop phosphatase
inhibitor (Roche). Insoluble material was pelleted by
centrifugation at 14,000 × g for 10 min at 4°C. Protein
concentration was determined by DC Assay (BioRad)
and samples were diluted to 1 mg/ml in lysis buffer.
Samples were precleared with 5 μl Protein A/G Plus
beads (SCBT) for 1 h. FLAG-tagged PAK2 was immuno-
precipitated by incubating precleared samples with 10 μl
anti-FLAG M2 agarose (Sigma-Aldrich) for 16 h at 4°C.
Beads were pelleted at 5000 × g for 30 seconds and
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by boiling beads with 2X SDS sample buffer. Samples
were subjected to SDS-PAGE (12% polyacrylamide) and
transferred to PVDF for Western blotting. Blots were
blocked with 5% milk in TBS + 0.05% Tween-20, and
then probed with HA-HRP (1:500, Roche), FLAG-HRP
(1:500, Sigma), anti-b-tubulin (1:1000, Sigma-Aldrich)
and anti-CDC42 (SCBT, 1:200).
Additional material
Additional file 1: Figure S1. CD25 Median FI (MFI) correlates
positively with peak p24 concentration and inversely with Nef-
mediated enhancement of viral replication. A. Correlation between
peak p24 concentrations from SF2 virus replication and CD25 MFI of the
CD3+ population in cultures stimulated with 1 μg/ml PHA-P, 2 μg/ml
PHA-P, and aCD3/CD28-coated beads. B. Correlation between (Peak p24
concentration of SF2 virus - peak p24 concentration of Nef)/peak p24
concentration of SF2 virus replication versus CD25 MFI of the CD3+
population. Spearman correlation was performed using GraphPad Prism.
Additional file 2: Figure S2. Reducing a-CD3/CD28-coated bead
concentration enhances Nef-mediated enhancement of T cell
activation. 50,000
3H cpm of RT activity of VSV-G pseudotyped pHAGE-
IRES zsGreen vectors was incubated overnight with 2.5 × 10
6 Jurkat E6.1
cells. 18 h post-transduction 2 × 10
5 transduced cells were stimulated
with the indicated concentration of a-CD3/CD28-coated beads or left
unstimulated for 16 h in one well of a 96-well U-bottom plate. Cells
were then stained for CD25. CD25 and zsGreen expression were
determined by flow cytometry. %CD25+ of the zsGreen population is
reported for duplicate cultures. Average %CD25+ for duplicate samples ±
SEM is shown. *p < 0.05 and ** p < 0.005 (Student’s t-test).
Additional file 3: Figure S3. Nef-mediated enhancement of
activation is not detected after 8 hours stimulation with a-CD3/
CD28 beads. Experiments were carried out as in Figure 3. 200,000
3H
cpm of RT activity of VSV-G pseudotyped virus was incubated overnight
with 10
6 Jurkat cells stably expressing NFAT-Luc. Infected cells were then
incubated with 10
6 a-CD3/CD28 beads for 8 h. Cells were lysed with 500
μl passive lysis buffer. The lysate was freeze/thawed once and luciferase
activity was assayed by luminescence. Average luciferase activity for
duplicate samples ± SEM is shown.
Additional file 4: Figure S4. Nef-mediated enhancement of
activation is not detected after 18 hours stimulation with 1 μg/ml
PHA-P. 50,000
3H cpm of RT activity of VSV-G pseudotyped pHAGE- IRES
zsGreen vectors (wild-type 5C, PAK2-association defective mutant 5C-7
(F89H, H191F), or empty Vector) was incubated overnight with 2.5 × 10
6
Jurkat E6.1 cells. 18 h post-transduction 2 × 10
5 transduced cells were
stimulated with 1 μg/ml PHA-P for 18 or 24 h or left unstimulated for 18
h in one well of a 96-well U-bottom plate. Cells were then stained for
CD25. CD25 and zsGreen expression were determined by flow cytometry.
%CD25+ of the zsGreen population is reported for duplicate cultures.
Average %CD25+ for triplicate samples ± SEM is shown. *p < 0.05 and **
p < 0.005 (Student’s t-test).
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